Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 18/20 | 0.77 |
| ▸ | SLC5A2 | P31639 | 18/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153046 | 0.92 | SLC5A2 (0.74) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12153036 | 0.91 | SLC5A2 (0.73) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12153044 | 0.91 | SLC5A2 (0.72) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12152976 | 0.87 | SLC5A2 (1.00) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12152992 | 0.86 | SLC5A1 (0.78) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12153012 | 0.84 | SLC5A2 (1.00) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12153024 | 0.84 | SLC5A2 (1.00) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL14528378 | 0.84 | SLC5A1 (0.54) | SLC5A1SLC5A2CYP3A4CA1CA2 | |
| SCHEMBL12152979 | 0.84 | SLC5A2 (1.00) | SLC5A1SLC5A2CYP3A4 | |
| SCHEMBL12153006 | 0.83 | SLC5A2 (0.78) | SLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | SLC5A1 1/4885SLC5A2 3/4885CYP3A4 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.